82233 CPT® code: payer coverage and prior authorization1 of 1 payer prior-auth lists that name 82233 require prior authorization or set conditions: Blue Shield of California Promise Health Plan.
| Payer | Plan | State | Prior auth | Conditions | Since | Source |
|---|---|---|---|---|---|---|
| Blue Shield of California Promise Health Plan | Promise Health Plan Medi-Cal | CA | prior auth required | Sep 1, 2026 | Medi-Cal Prior Authorization List |
82233 appears in 11 coverage policies from Aetna, Anthem, Blue Cross & Blue Shield of Mississippi, Blue Cross & Blue Shield of Rhode Island, Blue Cross NC, Blue Shield of California, BlueCross BlueShield of South Carolina, Premera Blue Cross, Regence.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Alzheimer's Disease Tests (0349) | covered if criteria are met | Aug 4, 2026 | payer document |
| Anthem | Testing for Biochemical Markers for Alzheimer Disease (LAB.00046) | covered if criteria are met | May 14, 2026 | payer document |
| Anthem | Testing for Biochemical Markers for Alzheimer Disease (LAB.00046) | not covered | May 14, 2026 | payer document |
| Blue Cross & Blue Shield of Mississippi | Evaluation Of Biomarkers For Alzheimer Disease | listed, no stance | payer document | |
| Blue Cross & Blue Shield of Rhode Island | Evaluation of Biomarkers for Alzheimer’s Disease | covered if criteria are met | Jul 2, 2025 | payer document |
| Blue Cross & Blue Shield of Rhode Island | Evaluation of Cerebrospinal Fluid, Urine and Plasma Tests for Alzheimer’s Disease | covered if criteria are met | Sep 2, 2026 | payer document |
| Blue Cross NC | Biochemical Markers of Alzheimer Disease and Dementia AHS – G2048 | listed, no stance | Oct 1, 2025 | payer document |
| Blue Cross NC | Professional Pathology Billing Requirements AHS – R2169 | listed, no stance (range 82009-82958) | Mar 1, 2024 | payer document |
| Blue Shield of California | Evaluation of Cerebrospinal fluid, Urine, and Plasma Tests for Alzheimer Disease (2.04.14) | listed, no stance | payer document | |
| BlueCross BlueShield of South Carolina | Biochemical Markers of Alzheimer Disease and Dementia (CAM 335) | listed, no stance | Oct 1, 2025 | payer document |
| Premera Blue Cross | (effective November 6, 2026) Evaluation of Cerebrospinal Fluid, Urine, and Plasma Tests for Alzheimer Disease (2.04.521) Page | 4 of 37 | ∞ | listed, no stance | Jul 14, 2026 | payer document |
| Regence | Biochemical and Cellular Markers of Alzheimer's Disease (Laboratory 22) | listed, no stance | Jun 1, 2026 | payer document |
Prior authorization required or conditional in VT, WA, WV.
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.